Nexalin Technology, Inc. - Common Stock (NQ:NXL)

0.4311 -0.0388 (-8.26%)

Streaming Delayed Price Updated: 4:00 PM EDT, Apr 23, 2026 Add to My Watchlist

Price and Volume

Volume	160,326
Open	0.4605
Bid (Size)	0.4205 (2,000)
Ask (Size)	0.4800 (9,000)
Prev. Close	0.4699
Today's Range	0.4201 - 0.4649
52wk Range	0.3302 - 2.000
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Nexalin Technology Advances Pivotal Clinical Trial of HALO™ Clarity Toward Q2 2026 Enrollment

April 22, 2026

160-participant, triple-blinded, sham-controlled study designed to support planned De Novo FDA submission for moderate-to-severe insomnia

From Nexalin Technology, Inc.

Via GlobeNewswire

RedChip's Biotech Investor Conference Replays Now Available

April 20, 2026

Via ACCESS Newswire

Performance

YTD	-26.0%	-26.0%
1 Month	+6.2%	+6.2%
3 Month	-30.9%	-30.9%
6 Month	-71.5%	-71.5%
1 Year	-75.2%	-75.2%

More News

Nexalin Advances FDA Alzheimer’s Strategy Following Landmark Leadership Meetings in the U.S. and China

April 15, 2026

From Nexalin Technology, Inc.

Via GlobeNewswire

Join Nexalin’s Exclusive Live Investor Webinar and Q&A Session on April 21

April 14, 2026

From Nexalin Technology, Inc.

Via GlobeNewswire

Nexalin Announces Peer-Reviewed Study Showing the Company’s DIFS™ Technology Reduced Self-Injury and Depression Symptoms in Female Adolescents

April 09, 2026

From Nexalin Technology, Inc.

Via GlobeNewswire

RedChip Showcases Public Companies Driving Biotech Innovation at April 16 Virtual Investor Conference

April 02, 2026

Via ACCESS Newswire

Nexalin Announces Pivotal HALO™ Clarity Trial to Support Planned De Novo FDA Submission Targeting Multi-Billion-Dollar Insomnia Market

February 24, 2026

From Nexalin Technology, Inc.

Via GlobeNewswire

Nexalin Participates in and Commends Recent Congressional Momentum Supporting Deep Brain Neurostimulation Research for Veterans and Neurological Disorders

February 23, 2026

From Nexalin Technology, Inc.

Via GlobeNewswire

Nexalin Technology and First Phosphate Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

February 13, 2026

Via ACCESS Newswire

Unusual volume stocks in Friday's session ↗

February 06, 2026

Via Chartmill

Nexalin Launches NeuroCare®, an AI-Driven Virtual Clinic Designed to Transform Access for Patients with Alzheimer’s, Mood Disorders, TBI & PTSD Care

February 05, 2026

From Nexalin Technology, Inc.

Via GlobeNewswire

Discover the top movers in Thursday's pre-market session. ↗

February 05, 2026

Via Chartmill

Top movers in Tuesday's pre-market session ↗

February 03, 2026

Via Chartmill

Nexalin Highlights its Expanding Body of Peer-Reviewed Neuroimaging Research Confirming its DIFS™ Technology as the Leader in Evidenced-Based Non-Invasive Brain Stimulation

February 02, 2026

From Nexalin Technology, Inc.

Via GlobeNewswire

Nexalin Technology Receives Nasdaq Listing Status Notification

January 23, 2026

From Nexalin Technology, Inc.

Via GlobeNewswire

Published Peer-Reviewed Study Demonstrates Nexalin’s DIFS™ Neurostimulation Improves Attention and Normalizes Brain Activity in Patients with ADHD

January 14, 2026

From Nexalin Technology, Inc.

Via GlobeNewswire

Nexalin Technology Completes FDA Q-Submission Meeting for Gen-2 SYNC™ Neurostimulation Console in Alzheimer’s Disease Program

December 03, 2025

From Nexalin Technology, Inc.

Via GlobeNewswire

Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on December 4

December 02, 2025

From Nexalin Technology, Inc.

Via GlobeNewswire

Wondering what's happening in today's pre-market session? ↗

November 19, 2025

Via Chartmill

Nexalin’s 15 Milliamp Neurostimulation Device Demonstrates Promising Results in Treating Gambling Disorder with Alcohol Use Comorbidity

November 18, 2025

From Nexalin Technology, Inc.

Via GlobeNewswire

Nexalin Technology Appoints Carmi Masha Technologies Ltd. as Exclusive Distributor in Israel

November 13, 2025

From Nexalin Technology, Inc.

Via GlobeNewswire

Nexalin Technology’s Q-Submission for Gen-2 SYNC Accepted by U.S. FDA for the Treatment of Alzheimer’s Disease and Dementia

November 05, 2025

From Nexalin Technology, Inc.

Via GlobeNewswire

Nexalin Technology Announces Regulatory Approval to Sell Gen 2 SYNC, 15 mA Neurostimulation DIFS™ Device in Israel

October 30, 2025

From Nexalin Technology, Inc.

Via GlobeNewswire

Nexalin’s DIFS™ Neurostimulation Shows Cognitive and Brain Network Improvements in Alzheimer’s and Dementia Across Three Peer-Reviewed Studies

October 21, 2025

From Nexalin Technology, Inc.

Via GlobeNewswire

Nexalin Technology and BioVie Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

October 17, 2025

Via ACCESS Newswire

Frequently Asked Questions

Is Nexalin Technology, Inc. - Common Stock publicly traded?

Yes, Nexalin Technology, Inc. - Common Stock is publicly traded.

What exchange does Nexalin Technology, Inc. - Common Stock trade on?

Nexalin Technology, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Nexalin Technology, Inc. - Common Stock?

The ticker symbol for Nexalin Technology, Inc. - Common Stock is NXL on the Nasdaq Stock Market

What is the current price of Nexalin Technology, Inc. - Common Stock?

The current price of Nexalin Technology, Inc. - Common Stock is 0.4311

When was Nexalin Technology, Inc. - Common Stock last traded?

The last trade of Nexalin Technology, Inc. - Common Stock was at 04/23/26 04:00 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.